dihexa toxicity study Growth factors and their peptide mimetics for treatment of traumatic brain injury AngIV-Analog Dihexa Rescues Cognitive Impairment

Journal Medicine 116 (5), 358

Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy

101-104 Studies show compounds from ginkgo reduce oxidative and inflammatory endothelial cell injury and improve vascular function, inhibiting atherosclerotic plaque development and possibly decreasing the risk of arterial clots

Ozempic is included in the coverage of the Ontario Drug Benefit program, catering to eligible seniors aged 65 years and above